Francisco Silva - 18 Mar 2024 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role
VP of Research and Development, Director
Signature
/s/ Franisco Silva
Issuer symbol
BRTX
Transactions as of
18 Mar 2024
Net transactions value
-$23,898
Form type
4
Filing time
20 Mar 2024, 16:38:57 UTC
Previous filing
15 Feb 2024
Next filing
10 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BRTX Common Stock Tax liability $23,898 -17,193 -10% $1.39 147,451 18 Mar 2024 Direct F1
holding BRTX Common Stock 12,136 18 Mar 2024 IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BRTX Stock Option 9 18 Mar 2024 Common Stock 9 $3000.00 Direct F2
holding BRTX Stock Option 6 18 Mar 2024 Common Stock 6 $3000.00 Direct F2
holding BRTX Stock Option 15 18 Mar 2024 Common Stock 15 $3000.00 Direct F2
holding BRTX Stock Option 20 18 Mar 2024 Common Stock 20 $3000.00 Direct F2
holding BRTX Stock Option 25 18 Mar 2024 Common Stock 25 $3000.00 Direct F2
holding BRTX Stock Option 293,479 18 Mar 2024 Common Stock 293,479 $5.08 Direct F2
holding BRTX Stock Option 42,059 18 Mar 2024 Common Stock 42,059 $5.08 Direct F3
holding BRTX Stock Option 106,762 18 Mar 2024 Common Stock 106,762 $2.91 Direct F4
holding BRTX Stock Option 394,737 18 Mar 2024 Common Stock 394,737 $1.45 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were withheld from vested stock grant to pay the associated withholding taxes.
F2 The option is currently exercisable.
F3 The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 and 21,029 shares in eight nearly equal quarterly installments beginning November 4, 2022 and continuing every three months thereafter until fully vested.
F4 The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
F5 The option vests and becomes exercisable to the extent of 197,369 shares on February 13, 2024 and 197,368 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested.